-
Product Insights
NewNet Present Value Model: Ideaya Biosciences Inc’s IDE-161
Empower your strategies with our Net Present Value Model: Ideaya Biosciences Inc's IDE-161 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Ideaya Biosciences Inc’s Darovasertib
Empower your strategies with our Net Present Value Model: Ideaya Biosciences Inc's Darovasertib report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Ideaya Biosciences Inc’s IDE-397
Empower your strategies with our Net Present Value Model: Ideaya Biosciences Inc's IDE-397 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Ideaya Biosciences Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Ideaya Biosciences Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TransCon IL-2 Beta/Gamma in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TransCon IL-2 Beta/Gamma in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TransCon IL-2 Beta/Gamma in Cervical Cancer Drug Details: Recombinant...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadunolimab in Extrahepatic Bile Duct Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadunolimab in Extrahepatic Bile Duct Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadunolimab in Extrahepatic Bile Duct Cancer Drug Details: Nadunolimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IDE-161 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDE-161 in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDE-161 in Prostate Cancer Drug Details: IDE-161 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IDE-161 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDE-161 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDE-161 in Gastric Cancer Drug Details: IDE-161 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IDE-161 in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDE-161 in Metastatic Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDE-161 in Metastatic Ovarian Cancer Drug Details: IDE-161 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IDE-161 in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDE-161 in Colon Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDE-161 in Colon Cancer Drug Details: IDE-161 is under development for the treatment...